WASHINGTON (AP) — A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients.
Scientists took patients’ own immune cells and turned them into “living drugs” able to recognize and attack glioblastoma. In the first-step tests, those cells shrank tumors at least temporarily, researchers reported Wednesday.
So-called CAR-T therapy already is used to fight blood-related cancers like leukemia but researchers have struggled to make it work for solid tumors. Now separate teams at Massachusetts General Hospital and the University of Pennsylvania are developing next-generation CAR-T versions designed to get past some of glioblastoma’s defenses.
“It’s very early days,” cautioned Penn’s Dr. Stephen Bagley, who led one of the studies. But “we’re optimistic that we’ve got something to build on here, a real foundation.”
Who is Jacob Zuma, the former South African president disqualified from next week's election?
PSG defender Hernandez needs surgery after rupturing ACL and set to miss Euro 2024
Farmer who demolished a 17th century Grade II listed dovecote without permission is fined £45,000
Farmer who demolished a 17th century Grade II listed dovecote without permission is fined £45,000
Georgia Republicans choose Amy Kremer, organizer of pro
Lawmakers in Serbia elect new government with pro
Pennsylvania nurse who gave patients lethal or possibly lethal insulin doses gets life in prison
Police in Fort Worth say four children are among six people wounded in a drive
Company wins court ruling to continue development of Michigan factory serving EV industry
Police in Fort Worth say four children are among six people wounded in a drive
Liverpool confirms Arne Slot as Jurgen Klopp's replacement
Ricky Stenhouse Jr. signs multiyear extension with JTG Daugherty Racing for NASCAR Cup Series